1. Home
  2. TOP vs CELU Comparison

TOP vs CELU Comparison

Compare TOP & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Financial Group Limited

TOP

TOP Financial Group Limited

HOLD

Current Price

$0.76

Market Cap

36.3M

Sector

Finance

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$0.93

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOP
CELU
Founded
2015
2016
Country
Singapore
United States
Employees
N/A
123
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.3M
35.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TOP
CELU
Price
$0.76
$0.93
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
35.5K
41.5K
Earning Date
01-20-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.88
52 Week High
$3.33
$4.35

Technical Indicators

Market Signals
Indicator
TOP
CELU
Relative Strength Index (RSI) 41.76 29.06
Support Level $0.75 N/A
Resistance Level $1.13 $1.46
Average True Range (ATR) 0.04 0.09
MACD -0.00 -0.02
Stochastic Oscillator 19.15 8.33

Price Performance

Historical Comparison
TOP
CELU

About TOP TOP Financial Group Limited

TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: